Halozyme Therapeutics

Halozyme initiates randomized phase II trial of PEGPH20 in pancreatic cancer

Thursday, April 25, 2013 08:00 AM

Halozyme Therapeutics, a San Diego-based biopharmaceutical company, initiated a phase II multicenter, randomized clinical trial evaluating PEGPH20, a proprietary, investigational drug as a first-line therapy for patients with stage IV metastatic pancreatic cancer.

More... »

Roche’s Herceptin phase III trial shows positive results

Tuesday, October 18, 2011 09:45 AM

Halozyme Therapeutics has reported that the phase III HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous (IV) infusion. The SC administration takes around 5 minutes to administer whereas the IV formulation (the current standard) takes around 30 minutes to infuse. Since the subcutaneous administration is an injection under the skin it may allow patients to spend less time in hospital receiving their treatment versus the intravenous method. The ready to use formulation may also significantly reduce pharmacy time as no medicine preparation time is required.

More... »

Halozyme launches phase II pancreatic cancer trial

Thursday, October 6, 2011 10:47 AM

Halozyme Therapeutics has reported the commencement of patient dosing in a phase II clinical trial with pegylated rHuPH20 (PEGPH20) in patients with stage IV previously untreated pancreatic cancer. This multi-center, international, randomized, placebo-controlled trial will study the safety, tolerability and efficacy of gemcitabine plus PEGPH20 compared to gemcitabine plus placebo.

More... »

Halozyme's ultrafast insulin demonstrates reduced variability of insulin absorption

Sunday, June 26, 2011 08:46 PM

Halozyme Therapeutics has announced final results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog, reduces the variability of insulin absorption and reduces post-meal glycemic excursions compared to NovoLog alone.

More... »

Halozyme's ultrafast insulin study shows positive results

Friday, April 15, 2011 12:41 PM

Halozyme Therapeutics reports results from a study in type I diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLogR, accelerates insulin absorption and shortened its duration of action. These preliminary results represent the first reported experience in a clinical trial where patients received rHuPH20 enzyme combined with an insulin analog as a continuous subcutaneous insulin infusion (CSII) over 72 hours administered with an insulin pump.

More... »